| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6770262 | EVOKE PHARMA INC | Nasal administration of agents for the treatment of gastroparesis |
Mar, 2021
(3 years ago) | |
| US11020361 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(5 years from now) | |
| US11628150 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(5 years from now) | |
| US11813231 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(5 years from now) | |
| US8334281 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
May, 2030
(6 years from now) | |
Gimoti is owned by Evoke Pharma Inc.
Gimoti contains Metoclopramide Hydrochloride.
Gimoti has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Gimoti are:
- US6770262
Gimoti was authorised for market use on 19 June, 2020.
Gimoti is available in spray, metered;nasal dosage forms.
Gimoti can be used as nasal administration of metoclopramide for treatment of diabetic gastroparesis.
The generics of Gimoti are possible to be released after 16 May, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED;NASAL
GIMOTI family patents
